Top Glove Corporation Bhd.

OTCPK:TPGV.F Stock Report

Market Cap: US$2.3b

Top Glove Corporation Bhd Valuation

Is TPGV.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TPGV.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TPGV.F ($0.3) is trading above our estimate of fair value ($0.3)

Significantly Below Fair Value: TPGV.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TPGV.F?

Key metric: As TPGV.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TPGV.F. This is calculated by dividing TPGV.F's market cap by their current revenue.
What is TPGV.F's PS Ratio?
PS Ratio4.4x
SalesRM 2.52b
Market CapRM 10.50b

Price to Sales Ratio vs Peers

How does TPGV.F's PS Ratio compare to its peers?

The above table shows the PS ratio for TPGV.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2x
XRAY DENTSPLY SIRONA
1x1.1%US$3.9b
NEOG Neogen
2.9x4.6%US$2.6b
EMBC Embecta
1x0.7%US$1.2b
HAE Haemonetics
3x6.0%US$4.1b
TPGV.F Top Glove Corporation Bhd
4.4x24.0%US$10.5b

Price-To-Sales vs Peers: TPGV.F is expensive based on its Price-To-Sales Ratio (4.4x) compared to the peer average (2x).

Price to Sales Ratio vs Industry

How does TPGV.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

48 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.4%US$213.17m
ARAY Accuray
0.4x5.5%US$196.10m
NVRO Nevro
0.4x2.7%US$155.51m
OM Outset Medical
0.5x11.4%US$55.69m
TPGV.F 4.4xIndustry Avg. 3.2xNo. of Companies48PS02.85.68.411.214+
48 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TPGV.F is expensive based on its Price-To-Sales Ratio (4.4x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is TPGV.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TPGV.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TPGV.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TPGV.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$0.25
0%
19.3%US$0.34US$0.16n/a19
Dec ’25US$0.25
US$0.25
-2.1%
16.6%US$0.32US$0.16n/a19
Nov ’25US$0.20
US$0.25
+21.1%
16.6%US$0.32US$0.16n/a19
Oct ’25n/a
US$0.26
0%
18.6%US$0.35US$0.17n/a19
Sep ’25US$0.17
US$0.24
+38.2%
20.7%US$0.33US$0.16n/a19
Aug ’25US$0.21
US$0.22
+3.7%
21.9%US$0.31US$0.14n/a20
Jul ’25US$0.23
US$0.21
-5.5%
20.9%US$0.30US$0.13n/a20
Jun ’25US$0.22
US$0.18
-16.8%
23.0%US$0.26US$0.11n/a20
May ’25n/a
US$0.17
0%
18.3%US$0.23US$0.11n/a20
Apr ’25US$0.13
US$0.17
+31.2%
18.3%US$0.23US$0.11n/a20
Mar ’25US$0.14
US$0.17
+14.9%
19.0%US$0.23US$0.10n/a20
Feb ’25US$0.16
US$0.16
+4.8%
17.4%US$0.21US$0.11n/a20
Jan ’25US$0.19
US$0.17
-12.0%
17.4%US$0.22US$0.11n/a20
Dec ’24US$0.23
US$0.14
-35.8%
19.0%US$0.21US$0.10US$0.2519
Nov ’24n/a
US$0.14
0%
19.0%US$0.21US$0.10US$0.2019
Oct ’24US$0.13
US$0.16
+28.1%
27.3%US$0.29US$0.096n/a20
Sep ’24n/a
US$0.16
0%
27.3%US$0.29US$0.097US$0.1721
Aug ’24US$0.19
US$0.16
-16.1%
27.3%US$0.29US$0.096US$0.2121
Jul ’24n/a
US$0.16
0%
27.3%US$0.29US$0.096US$0.2321
Jun ’24US$0.25
US$0.16
-37.8%
31.4%US$0.30US$0.10US$0.2221
May ’24n/a
US$0.16
0%
27.1%US$0.24US$0.10n/a21
Apr ’24US$0.18
US$0.16
-13.9%
26.7%US$0.24US$0.10US$0.1321
Mar ’24n/a
US$0.13
0%
26.8%US$0.24US$0.074US$0.1421
Feb ’24US$0.16
US$0.14
-9.3%
48.1%US$0.43US$0.075US$0.1621
Jan ’24US$0.18
US$0.14
-23.4%
48.2%US$0.41US$0.072US$0.1921
Dec ’23US$0.16
US$0.14
-10.9%
43.6%US$0.41US$0.10US$0.2321

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 17:55
End of Day Share Price 2024/12/10 00:00
Earnings2024/08/31
Annual Earnings2024/08/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Top Glove Corporation Bhd. is covered by 38 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ken-Wern LimAffin Hwang Investment Bank
Nafisah AzmiAmInvestment Bank Berhad
Pak ThongAmInvestment Bank Berhad